BR112017005133A2 - métodos para intensificar, melhorar ou manter saúde e/ou função cognitiva, para tratar ou prevenir um declínio na saúde e/ou função cognitiva, e para melhorar humor e sono em um mamífero - Google Patents

métodos para intensificar, melhorar ou manter saúde e/ou função cognitiva, para tratar ou prevenir um declínio na saúde e/ou função cognitiva, e para melhorar humor e sono em um mamífero

Info

Publication number
BR112017005133A2
BR112017005133A2 BR112017005133A BR112017005133A BR112017005133A2 BR 112017005133 A2 BR112017005133 A2 BR 112017005133A2 BR 112017005133 A BR112017005133 A BR 112017005133A BR 112017005133 A BR112017005133 A BR 112017005133A BR 112017005133 A2 BR112017005133 A2 BR 112017005133A2
Authority
BR
Brazil
Prior art keywords
function
cognitive health
improving
sleep
mammal
Prior art date
Application number
BR112017005133A
Other languages
English (en)
Inventor
Lewis Brandon
Herrlinger Kelli
Nieman Kristin
Ceddia Michael
Feng Shulin
Original Assignee
Kemin Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Ind Inc filed Critical Kemin Ind Inc
Publication of BR112017005133A2 publication Critical patent/BR112017005133A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

extratos de plantas da família lamiaceae, incluindo o mentha genus, são mostradas para ter um impacto positivo na saúde cognitiva global, incluindo melhoras na memória, raciocínio, atenção/concentração, planejamento, humor, sono e comportamentos associados. os produtos de saúde cognitiva atuais têm mostrado apenas benefício no estudo cruzado, agudo, e têm resultados inconsistentes. assim, existe uma necessidade por extratos botânicos naturais com eficácia comprovada seguindo suplementação crônica.
BR112017005133A 2014-09-15 2015-09-15 métodos para intensificar, melhorar ou manter saúde e/ou função cognitiva, para tratar ou prevenir um declínio na saúde e/ou função cognitiva, e para melhorar humor e sono em um mamífero BR112017005133A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050563P 2014-09-15 2014-09-15
PCT/US2015/050230 WO2016044299A1 (en) 2014-09-15 2015-09-15 Plant extracts for improving cognitive function

Publications (1)

Publication Number Publication Date
BR112017005133A2 true BR112017005133A2 (pt) 2018-01-23

Family

ID=55453722

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005133A BR112017005133A2 (pt) 2014-09-15 2015-09-15 métodos para intensificar, melhorar ou manter saúde e/ou função cognitiva, para tratar ou prevenir um declínio na saúde e/ou função cognitiva, e para melhorar humor e sono em um mamífero

Country Status (8)

Country Link
US (2) US10857195B2 (pt)
EP (1) EP3194028A4 (pt)
JP (3) JP2017527591A (pt)
KR (2) KR20170054501A (pt)
AU (1) AU2015317990B2 (pt)
BR (1) BR112017005133A2 (pt)
CA (1) CA2961378A1 (pt)
WO (1) WO2016044299A1 (pt)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752476A (en) * 1986-02-18 1988-06-21 Copney Claudette V Sleep aiding herbal composition and method of utilizing same
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
JP2002275061A (ja) * 2001-03-19 2002-09-25 Tsumura & Co 抗うつ・抗不安剤
JP3947149B2 (ja) * 2002-10-28 2007-07-18 高砂香料工業株式会社 消臭剤組成物
CN1566300A (zh) * 2003-07-09 2005-01-19 新疆芳香植物科技开发股份有限公司 制造香囊、香枕的芳香组合物及其制备方法
JP2005053891A (ja) * 2003-07-18 2005-03-03 Seresu Corporation:Kk リパーゼ阻害剤
US20050031761A1 (en) * 2003-08-05 2005-02-10 Donald Brucker Methods of producing a functionalized coffee
JP2006199666A (ja) * 2005-01-24 2006-08-03 Nagase & Co Ltd 健忘症の予防・治療剤
EP1930019A1 (en) * 2006-11-24 2008-06-11 DSMIP Assets B.V. Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses
US20100137433A1 (en) * 2007-01-24 2010-06-03 Laima Kott Production of Rosmarinic Acid from Spearmint and uses Thereof
WO2008122099A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Composition for promoting sleep and relaxation comprising lemon balm
EP2060192B9 (en) * 2007-10-17 2016-05-04 Rudolf Wild GmbH & Co. KG Composition comprising lemon balm extracts
CN102014943A (zh) * 2008-02-25 2011-04-13 雀巢产品技术援助有限公司 包含例如迷迭香或葛缕子提取物的用于促进骨生长和维持骨健康的营养组合物
EP2398340A2 (en) * 2009-02-20 2011-12-28 DSM IP Assets B.V. Oregano extract for alertness
US20110151033A1 (en) * 2009-12-21 2011-06-23 Biotropics Malaysia Bhd Orthosiphon stamineus extracts for use as a cognition enhancer
JP5668258B2 (ja) * 2011-10-21 2015-02-12 ザ マッキス カンパニー インコーポレイテッド エゴマの葉マッコリ及びその製造方法
US20140044813A1 (en) * 2012-08-09 2014-02-13 Kemin Industries, Inc. Plant Extracts for Improving Cognitive Health and Function
US20140302170A1 (en) * 2013-04-08 2014-10-09 Scientific Nutrition Products, Inc. Compositions and methods for promoting sleep
CN106163512B (zh) * 2014-01-30 2021-10-22 凯敏工业公司 改善认知功能的植物提取物

Also Published As

Publication number Publication date
AU2015317990A1 (en) 2017-04-06
WO2016044299A1 (en) 2016-03-24
KR20170054501A (ko) 2017-05-17
KR20240000637A (ko) 2024-01-02
JP2017527591A (ja) 2017-09-21
CA2961378A1 (en) 2016-03-24
US10857195B2 (en) 2020-12-08
AU2015317990B2 (en) 2020-04-30
US20160074459A1 (en) 2016-03-17
JP2022084873A (ja) 2022-06-07
EP3194028A4 (en) 2018-10-10
EP3194028A1 (en) 2017-07-26
US20160166629A1 (en) 2016-06-16
JP2024075715A (ja) 2024-06-04

Similar Documents

Publication Publication Date Title
ECSP16081503A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
ECSP17029218A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EA201791725A1 (ru) Способы ухода за кожей
GT201600249A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
EA201791811A1 (ru) Лечение панкреатита
BR112016019825A2 (pt) anticorpos do fator bb do complemento
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
DOP2017000098A (es) Compuesto heterocíclico
EA201992248A1 (ru) АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
ECSP19072372A (es) Moduladores de la expresión de pcsk9
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
CL2019000670A1 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso.
BR112016017612A2 (pt) Uso de um extrato de uma planta do gênero mentha da família lamiaceae
TW201613628A (en) Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders
BR112016029008A2 (pt) uso de sulfato de dextrana com peso molecular médio abaixo de 10000 da para induzir a angiogênese em um sujeito
BR112017009448A2 (pt) método para tratamento da doença de huntington, método para desaceleração da progressão de atrofias cerebral e estriatal em um indivíduo acometido de doença neurodegenerativa, e método para tratamento de distonia em um indivíduo acometido de uma doença neurodegenerativa
MX2020003554A (es) Moduladores de la expresion de enac.
BR112016019286A2 (pt) anticorpos do componente c5 do complemento
BR112017005133A2 (pt) métodos para intensificar, melhorar ou manter saúde e/ou função cognitiva, para tratar ou prevenir um declínio na saúde e/ou função cognitiva, e para melhorar humor e sono em um mamífero

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]